Astellas Pharma Inc (YPH MU) stock market data APIs
€9.8216
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
Astellas Pharma Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for YPH.MU.
Prev. Close
9.8216
Open
9.8216
High
9.8216
Low
9.8216
52 wk Range
7.862-10.6357
Market Cap
25 701 M
Dividends (Yield)
1.4099
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Pfizer (PFE), Astellas Post Favorable Trial Results for Bladder Cancer Combo
Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy. On August 12, Pfizer and Astellas Pharma reported that their combination therapy for muscle-invasive bladder cancer had positive outco...
Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study
Pfizer recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma, showing significant improvements in event-free and overall survival for bladder...
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible fo...
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder c...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
